Full-Time

Senior Quantitative Researcher

Options Market Making

Maven Securities

Maven Securities

201-500 employees

Proprietary-capital multi-strategy trading and market making

No salary listed

London, UK

In Person

Category
Quantitative Finance (1)
Requirements
  • Academic degree in applied mathematics, computer science, statistics engineering or physics
  • PhD or any other track record in conducting independent research
  • Minimum 3+ years of experience in the financial industry, particularly electronic options trading
  • Ability to research advanced algorithms, develop predictive models and verify complex hypotheses using large datasets
  • Proactive interest in improving existing trading strategies and identifying new opportunities
  • A collaborative bridge between developers, and traders who aligns technical work with commercial impact and the broader strategic vision, and a real team player with other quants in the team.
Responsibilities
  • Lead projects that have a direct impact on trading performance.
  • Collaborate with researchers and traders from various scientific fields and institutions to develop innovative real-time trading models and solutions for low latency trading systems for exchange-traded options.
  • Share knowledge with other researchers to tackle challenging projects including but not limited to option pricing and volatility models, algorithm design and alpha research.

Maven Securities trades and provides market liquidity across global financial markets using its own capital. It combines fundamental and quantitative methods to find trading opportunities and to execute trades efficiently from front office to settlements. The firm differentiates itself by using exclusively proprietary capital, strong risk controls, and a focus on technology to improve execution. Its goal is to earn sustainable profits while keeping markets liquid for institutional clients and other traders.

Company Size

201-500

Company Stage

N/A

Total Funding

N/A

Headquarters

London, United Kingdom

Founded

2011

Simplify Jobs

Simplify's Take

What believers are saying

  • MBX Biosciences' canvuparatide shows 63% Phase 2 response rate, targeting $61 stock.
  • Stifel and UBS issue Buy ratings on MBX with $50-$60 targets for pipeline progress.
  • Maven allocates internal capital flexibly, ensuring alignment and robust returns always.

What critics are saying

  • MBX 4291 Phase 1b obesity data fails in Q4 2026, wiping biotech investment value.
  • Canvuparatide Phase 3 stalls within 12 months, collapsing MBX's lead program valuation.
  • MBX exhausts cash runway in 18 months, forcing dilutive raises that shrink Maven's stake.

What makes Maven Securities unique

  • Deploys proprietary capital across discretionary, systematic, and market-making strategies.
  • Integrates machine learning and cutting-edge tech for algorithmic trading excellence.
  • Provides liquidity in global listed derivatives with tight pricing during volatility.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401K Scheme

25 Days Annual Leave plus public holidays

Healthcare, Dental & Vision

Employee Volunteering Opportunities

Annual Discretionary Bonus

Company News

MarketBeat
Aug 21st, 2025
Maven Securities LTD Invests $4 Million in StandardAero, Inc. $SARO

Maven Securities LTD has invested approximately $4 million in StandardAero, acquiring a stake of 150,000 shares as of the first quarter of 2023.

ETF Daily News
Apr 2nd, 2025
Corebridge Financial Inc. Has $2.37 Million Stock Position in Sotera Health (NASDAQ:SHC)

Maven Securities LTD acquired a new stake in Sotera Health in the 3rd quarter valued at approximately $1,670,000.

MarketBeat
Mar 2nd, 2025
Rithm Capital Corp. (NYSE:RITM) Shares Sold by Y Intercept Hong Kong Ltd

Soros Fund Management LLC acquired a new stake in Rithm Capital in the 3rd quarter valued at about $23,835,000.

MarketBeat
Jan 19th, 2025
Rithm Capital Corp. (NYSE:RITM) Receives $12.94 Consensus Price Target from Brokerages

Finally, Maven Securities LTD purchased a new stake in Rithm Capital in the 3rd quarter worth about $11,350,000.

ETF Daily News
Dec 18th, 2024
Wellington Management Group LLP Cuts Stake in Wave Life Sciences Ltd. (NASDAQ:WVE)

Maven Securities LTD purchased a new stake in Wave Life Sciences in the third quarter worth $6,970,000.